`
`GSK reades 500 reps for Horizari launch — FiercePlama
`
`<seIectanomersne I
`
`I
`SEWHESCIENC CAN
`SIGN ME UP
`
`REGENERON
`scrence to nverl/cme
`
`DO
`
`EMAIL ADDRESS
`
`Fiercepharma
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`GSK readies 500 reps for Horizant launch
`April 8. 2011
`| By Tracy Staton
`
`SHARE
`
`
`Now that they have FDA approval for Horizant in the bag, GlaxoSmithKline and
`Xenoport are working out a sales strategy. And if the companies‘ statistics hold
`true, there are more than 5 million Americans with symptoms of restless legs
`syndrome, all potential buyers for this new treatment.
`
`There's been plenty of debate about whether restless legs constitute a "real"
`syndrome and whether sufferers really need a drug. To combat those arguments,
`Xenoport has data suggesting the syndrome doesn't just consist of its trademark
`leg twitching and restless sleep, but may be linked to high blood pressure and
`heart disease. And the fact is, sufferers are seeking treatment.
`
`That's where Horizant comes in, beginning July 1, the companies say.
`GlaxoSmithKIine will field a sales force of some 500 reps, Xenoport CEO Ron
`Barrett told FierceBiotech. Among their targets: The 60,000 to 70,000 primary care
`doctors and neurologists who now write most of the scrips for restless legs
`treatment.
`
`jT.
`
`[Webinar] Physician Prescribing Trends 8. Opportunities for Health
`System-Pharma collaboration
`DATE: WEDNESDAY, MARCH 16 I 11AM ET IBAM PT
`athenahealth conducted a strdy D learn how health systems and new reimbursement models
`are impacting prescribing behavior. Well discuss our findings, including opportunities for
`phamia marketers, win a health system leader on our March 16th webinar. Reserve Your Spot
`Today!
`
`Xenoport itself has the right to co-rnarket the drug, but the company doesn't plan to
`do so right away, Barrett said. If it does decide to build up its own sales force, it
`would hire 50 to 100 reps to complement GSK's work. As Xconomy points out,
`Xenoporfs share of profits varies according to how much it contrimtes to the
`partnership with GSK.
`
`- read the Xconomy story
`— get more from the Los Angeles Times
`
`Related Articles:
`
`XenoPort rockets up after FDA approves Horizant for RLS
`
`lltp'lIwww.tiercep|'Iarna.cornIstuyIgsk-reade5-5(I)-reps-horizalt-lamchl201 1-04-08
`
`Page 1 of 2
`
`mowuseloo
`
`JOIN 150,000+ INSIDERS
`SIGN UP FOR OUR
`NEWSLETTER
`HercePharma is the phanna industry's daily monitor,
`with a special focus on phamlaceutical company
`news and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get Fr'err:ePhanna via daily email. Sign up today!
`ilvrrlvlr
`an IIl‘II‘lll
`EMAIL ADDRESS
`
`THE STORY IN ACTION
`
`cf ALTHEA | THE pawn: In Mm
`
`POPULAR STORIES
`
`MOST READ I MOST SHARED
`Doctors pounce on ‘alarmist,’ horrifying‘ Novartis
`heart—failure ad
`
`Top exec exits as Pfizer redraws org chart for post-
`megamerger future
`NICE, in reversal, OKs Amgen's Repatha while
`snubbing Sanoti and Regeneron's Praluent
`Some top GSK investors aren't sold on a breakup-
`and they're backing CEO Witty, too
`PhRMA kicks off new ad campaign to doctor
`pharma's tarred image
`
`Li THE LIBRARY: MULTIMEDIA
`FierceBiotech Radio on the burning hole in
`Gilead's $253 pocket and AbbVie's future in
`
`SENJU EXHIBIT 23070 1
`LUPIN V. SENJU
`
`/3
`
`IPR2015—0l105
`
`
`
`2/9/2016
`
`GSK realies 5tX) reps for Horizart larnch — Fiercefiama
`
`GSK, XenoPort revise Horizant pact
`
`I h9ma1°'°9Y
`
` j '°‘°E"’E" ""’°'5
`EMAIL ADDRESS
`SIGN MI: UP
`Fiemephannag cfly Hdfaflafl
`Fr'eIr:eBr'otecIr's Damian Gade
` liscuss the discussion around Gilead
`| Filed Under Glaxosrnillcile, Horizult, Phama sales reps, Resthn Leg Syndrome, Xenoport
`|
`Sciences'hugecashreserveandthemany
`lhingsthecompany mightbuy. Plus, aloolr
`baclr at AbbVle's bloclrbuster buyout at
`Pharmacyclics aid a comideration of how a
`certdn biotech entrepreneur is bring'ng
`atterlion to an FDA loophole.
`
`COMMENTS
`spammed
`
`I HATE Annuities...and So Should You!
`
`If you have a $500,000 portfolio, uncover the truth about annuities
`by reading "Annuity Insights" from Forbes columnist Ken Fishers
`firm.
`
`MORE ITEMS
`
`1 Comment
`
`Fierr:ePharma
`
`. Recommend
`
`B share
`
`Join the dscuss On‘ "
`
`LATEST COMMENTARY
`
`AstraZeneca chief chalks up milestones on his map
`to $458
`
`_
`0 Logrn
`
`What's the calendar bringing biophanna next year?
`.
`Our top 5 ideas
`
`so" by 395' V
`
`The most popular FiercePhanna stories of 2015
`Does new scrutiny threaten pharma's specialty-
`phannacy strategy?
`
`Pfizer responds to FiercePharma
`
`5 years ago
`Anonymous
`I can assure you RLS is a documented medical condition. I have had it since the age of
`
`12. As I age there have been times it has been so unbearable I have gone for weeks
`orl an hour or two of sleep per night. When I was put on mirapex my sleep improved
`100%. The problem is, with time, mirapex becomes less effective.
`
`Re9'1V'
`
`She"? '
`
`EVENTS
`
`Drug Development Immersion Course
`C
`"My 1748 20“; _ Wes‘ W I
`rprimegm a;ea)_ NJ — sponsored By:
`Fiewefliotech
`
`CB|'s Global Anti-Corruption and FCPA
`Compliance Congress
`Mach 1517. 2016 — Philadelphia, PA
`
`Exl's 2nd Procurement and Outsourcing
`Summit
`Mach 22-23, 2016 — The Inn d Pem, A
`Hilton Hotel — Phfladelphia, PA
`MORE EVENTS
`
`,
`
`L‘.
`;-"p,;:»‘: L"
`'=ns:>;
`*
`IMFSIIRIEI
`CIIIIPLETE THE
`SIIVEY TIMI!
`
`PRESS RELEASES
`
`FEATURED JOBS
`
`> Need a job? Need to hire? Visit our jobs site.
`
`consistent with the FDA label when specific conditions are met
`
`lmmunovia announces collaboration with Mount Sinai Health System to
`validate early detection blood test for pancreatic cancer in a prospective
`clinical study
`First patient treated with LC Bead LUMl"' radiopaque embolic bead
`supported by Philips live image guidance
`Amplyx Pharmaceuticals Expands Management Team and Increases Its
`Series B Financing to $49.2 Million
`SANOFI DELIVERED 2015 BUSINESS EPS UP 8.5% ON A REPORTED
`BASIS AND STABLE AT CONSTANT EXCHANGE RATES CONSISTENT
`WITH GUIDANCE
`
`CMS will cover percutaneous LAAC therapy for Medicare beneficiaries
`
`lflpjmwwjacqiumacumstaylgsk-reaies-5D—rqs-Iuizan-IamllIZ)11-04(B
`
`2/3
`
`Page 2 of 2
`
`